Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
Marketing leader behind growth of brands such as Cipladine, Maxirich, and Soak Shield takes on expanded responsibilities to drive portfolio growth and consumer engagement.
The expansion adds 100 m³ of reactor capacity, significantly strengthening Siegfried’s position among the world’s leading CDMOs for small-molecule drug substances
As per the Department of Pharmaceuticals, the sector has expanded its reach across the country while strengthening domestic production capabilities and innovation
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
AI-powered remote patient monitoring platform earns recognition at AI in Healthcare 2.0 for advancing continuous, preventive, and personalized healthcare delivery
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
